Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2014, Pages

  Fullerton, Birgit ^a   Jeitler, Klaus ^b   Seitz, Mirjam ^c   Horvath, Karl ^b   Berghold, Andrea ^b   Siebenhofer, Andrea ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Division of Endocrinology and Metabolism ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

CEREBROVASCULAR ACCIDENT; CHILD CARE; DIABETIC KETOACIDOSIS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; EUROPE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; MEDICAL RESEARCH; META ANALYSIS; MICROALBUMINURIA; MORTALITY; NORTH AMERICA; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN; ADULT; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; HYPERGLYCEMIA; KETOACIDOSIS; METABOLISM;

ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KETOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901212150     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009122.pub2     Document Type: Review

References (286)

1. Mühlhauser I, Bruckner I, Berger M, Cheta D, Jorgens V, Ionescu-Tirgoviste C, et al. Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Dusseldorf study. Diabetologia 1987;30(9):681-90. 2662556
2. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B. Subclinical neuropathy among diabetes control and complications trial participants without diagnosable neuropathy at trial completion: Possible predictors of incident neuropathy?. Diabetes Care 2007;30(10):2613-8. 2662558
3. Albers JW, Kenny DJ, Brown M, Greene D, Cleary PA, Lachin JM, et al. Effect of intensive diabetes treatment on nerve conduction the diabetes control and complications trial. Annals of Neurology 1995;38(6):869-80. 2662559
4. Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, et al. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care 2007;30(10):2646-8. 2662560
5. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl. 3):C19-C24. 2662561
6. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007;30(3):707-12. 2662562
7. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clinical Chemistry 2007;53(5):897-901. 2662563
8. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50(12):2553-61. 2662564
9. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial--revisited. Diabetes 2008;57(4):995-1001. 2662565
10. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Medical Care 2000;38(6):679-85. 2662566
11. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48(4):870-80. 2662567
12. Musen G, Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, et al. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care 2008;31(10):1933-8. 2662568
13. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine 22.12.2005;353(25):2643-53. 2662569
14. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2007;30(8):2107-12. 2662570
15. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. [Erratum appears in JAMA 1998 Nov 4;280(17):1484]. JAMA 1998;280(2):140-6. 2662571
16. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005;111(19):2446-53. 2662572
17. Schmidt LE, Cox MS, Buzzard IM, Cleary PA. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. The DCCT Research Group. Journal of the American Dietetic Association 1994;94(12):1392-7. 2662573
18. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. [Erratum appears in Diabetologia 2002 Jun;45(6):936]. Diabetologia 2001;44(10):1215-20. 2662574
19. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelyzn M, et al. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(3):361-76. 2662575
20. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelyzn M, et al. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. Archives of Ophthalmology 1995;113(1):36-51. 2662576
21. Szucs TD, Smala AM, Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]. [German]. Fortschritte der Medizin 1998;116(31):34-8. 2662577
22. The DCCT Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(11):1415-27. 2662578
23. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT). Update. Diabetes Care 1990;13(4):427-33. 2662579
24. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. The DCCT Research Group. Diabetes Care 1987 Jan-Feb;10(1):1-19. 2662580
25. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 1987;10(1):1-19. 2662581
26. The DCCT Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. [Erratum appears in Arch Ophthalmol 1998 Nov;116(11):1469]. Archives of Ophthalmology 1998;116(7):874-86. 2662582
27. The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. American Journal of Cardiology 1995;75(14):894-903. 2662583
28. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics 1994;125(2):177-88. 2662584
29. The DCCT Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1998;128(7):517-23. 2662585
30. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International 1995;47(6):1703-20. 2662586
31. The DCCT Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000;23(8):1084-91. 2662587
32. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. The Journal of Clinical Endocrinology and Metabolism 1987;65(1):30-6. 2662588
33. The DCCT Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial: The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1996;124(4):379-88. 2662589
34. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. The DCCT Research Group. American Journal of Medicine 1991;90(4):450-9. 2662590
35. The DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46(2):271-86. 2662591
36. The DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24(10):1711-21. 2662592
37. The DCCT Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996;19(3):195-203. 2662593
38. The DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.[Erratum appears in JAMA 1997 Jul 2;278(1):25]. JAMA 1996;276(17):1409-15. 2662594
39. The DCCT Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. American Journal of Obstetrics and Gynecology 1996;174(4):1343-53. 2662595
40. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102(4):647-61. 2662596
41. The DCCT Research Group. Protocol for the Diabetes Control and Complications Trial. 1987 http://www2.bsc.gwu.edu/bsc/docs/dcctprot.pdf (last accessed: 29.07.2013). 2662597
42. The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(11):1468-78. 2662598
43. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35(5):530-45. 2662599
44. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45(10):1289-98. 2662600
45. The DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41(4):416-23. 2662601
46. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1995;122(8):561-8. 2662602
47. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1993;329(14):977-86. 2662603
48. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44(8):968-83. 2662604
49. Wing RR, Cleary PA. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 1988;11(7):567-73. 2662605
50. de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Archives of Internal Medicine 2008;168(17):1867-73. 2662606
51. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: Possible predictors of incident neuropathy?. Diabetes Care 2007;30(10):2613-8. 2662608
52. Albers JW, Kenny DJ, Brown M, Greene D, Cleary PA, Lachin JM, et al. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Annals of Neurology 1995;38(6):869-80. 2662609
53. Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, et al. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the Diabetes Control and Complications Trial. Diabetes Care 2007;30(10):2646-8. 2662610
54. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21 Suppl 3:C19-C21. 2662611
55. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007;30(3):707-12. 2662612
56. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clinical Chemistry 2007;53(5):897-901. 2662613
57. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50(12):2553-61. 2662614
58. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial--revisited. Diabetes 2008;57(4):995-1001. 2662615
59. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Medical Care 2000;38(6):679-85. 2662616
60. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48(4):870-80. 2662617
61. Musen G, Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, et al. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care 2008;31(10):1933-8. 2662618
62. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine 22.12.2005;353(25):2643-53. 2662619
63. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2007;30(8):2107-12. 2662620
64. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.[Erratum appears in JAMA 1998 Nov 4;280(17):1484]. JAMA 1998;280(2):140-6. 2662621
65. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005;111(19):2446-53. 2662622
66. Schmidt LE, Cox MS, Buzzard IM, Cleary PA. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. The DCCT Research Group. Journal of the American Dietetic Association 1994;94(12):1392-7. 2662623
67. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. [Erratum appears in Diabetologia 2002 Jun;45(6):936]. Diabetologia 2001;44(10):1215-20. 2662624
68. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelyzn M, et al. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(3):361-76. 2662625
69. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelyzn M, et al. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. Archives of Ophthalmology 1995;113(1):36-51. 2662626
70. Szucs TD, Smala AM, Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]. [German]. Fortschritte der Medizin 1998;116(31):34-8. 2662627
71. The DCCT Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(11):1415-27. 2662628
72. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT). Update. Diabetes Care 1990;13(4):427-33. 2662629
73. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care 1987;10(1):1-19. 2662630
74. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. The DCCT Research Group. Diabetes Care 1987 Jan-Feb;10(1):1-19. 2662631
75. The DCCT Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. [Erratum appears in Arch Ophthalmol 1998 Nov;116(11):1469]. Archives of Ophthalmology 1998;116(7):874-86. 2662632
76. The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. American Journal of Cardiology 1995;75(14):894-903. 2662633
77. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics 1994;125(2):177-88. 2662634
78. The DCCT Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1998;128(7):517-23. 2662635
79. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International 1995;47(6):1703-20. 2662636
80. The DCCT Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000;23(8):1084-91. 2662637
81. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. The Journal of Clinical Endocrinology and Metabolism 1987;65(1):30-6. 2662638
82. The DCCT Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial: The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1996;124(4):379-88. 2662639
83. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. The DCCT Research Group. The American Journal of Medicine 1991;90(4):450-9. 2662640
84. The DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46(2):271-86. 2662641
85. The DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24(10):1711-21. 2662642
86. The DCCT Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996;19(3):195-203. 2662643
87. The DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. [Erratum appears in JAMA 1997 Jul 2;278(1):25]. JAMA 1996;276(17):1409-15. 2662644
88. The DCCT Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. American Journal of Obstetrics and Gynecology 1996;174(4):1343-53. 2662645
89. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102(4):647-61. 2662646
90. The DCCT Research Group. Protocol for the Diabetes Control and Complications Trial. 1987 http://www2.bsc.gwu.edu/bsc/docs/dcctprot.pdf (last accessed: 29.07.2013). 2662647
91. The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18(11):1468-78. 2662648
92. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35(5):530-45. 2662649
93. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45(10):1289-98. 2662650
94. The DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41(4):416-23. 2662651
95. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 1995;122(8):561-8. 2662652
96. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1993;329(14):977-86. 2662653
97. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44(8):968-83. 2662654
98. Wing RR, Cleary PA. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988;11(7):567-73. 2662655
99. de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Archives of Internal Medicine 2008;168(17):1867-73. 2662656
100. Holman RR, Dornan TL, Mayon-White V, Howard-Williams J, Orde-Peckar C, Jenkins L, et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1983;1(8318):204-8. 2662658
101. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism: Clinical and Experimental 1996;45(12):1508-13. 2662660
102. Viberti GC. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995;311(7011):973-7. 2662662
103. Barbosa J, Connett J, Fryd D, Sutherland D, Rao V, Anderson R, et al. The Minnesota Diabetes Complications Clinical Trial. The first three years. Acta Diabetologica Latina 1983;20(2):165-71. 2662664
104. Barbosa J, Johnson S. Severe hypoglycemia during maximized insulin treatment of diabetes in a randomized clinical trial. Diabetes Care 1983;6(1):62-3. 2662665
105. Barbosa J, Steffes MW, Sutherland DE, Connett JE, Rao KV, Mauer SM. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 1994;272(8):600-6. 2662666
106. Fryd DS, Migliori R, Simmons RL, Chavers B, Dunn D, Payne W, et al. Renal transplantation at the University of Minnesota during the 1980s. Clinical Transplants 1987;02:167-81. 2662667
107. Hung J, Menth L, Thompson MJ, Saner B, Rao KV, Barbosa J. The Minnesota Diabetes Complications Clinical Trial cognitive functions under long-term maximized and standard metabolic controls. Diabète & Métabolisme 1984;10(1):48-51. 2662668
108. Amthor KF, Dahl-Jorgensen K, Berg TJ, Skard Heier M, Sandvik L, Aagenaes O, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: The Oslo study. Diabetologia 1994;37(6):579-84. 2662670
109. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L. Effects of intensified insulin treatment on various lesions of diabetic retinopathy. American Journal of Ophthalmology 1985;100(5):644-53. 2662673
110. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L. Oscillatory potentials, macular recovery time, and diabetic retinopathy through 3 years of intensified insulin treatment. Ophthalmology 1988;95(10):1358-66. 2662674
111. Brinchmann-Hansen O, Dahl-Jørgensen K, Hanssen KF, Sandvik L. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Archives of Ophthalmology 1988;106(9):1242-6. 2662671
112. Brinchmann-Hansen O, Dahl-Jørgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ (Clinical research ed.) 1992;304(6818):19-22. 2662672
113. Dahl-Jorgensen K. Near-normoglycemia and late diabetic complications. The Oslo Study. Acta Endocrinologica. Supplementum 1987;284:1-38. 2662678
114. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal (Clinical Research Ed.) 1986;293(6556):1195-9. 2662675
115. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. British Medical Journal (Clinical Research Ed.) 1985;290(6471):811-5. 2662676
116. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo study. Acta Endocrinologica 1988;117(1):19-25. 2662677
117. Deckert T, Lauritzen T, Parvig HH, Christiansen JS, Steno Study Group. Effect of two years of strict metabolic functions in long term insulin-dependent diabetes. Diabetic Nephropathy 1984;3:6-10. 2662680
118. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991;34(3):164-70. 2662681
119. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983;1(8318):200-4. 2662682
120. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985;34 Suppl 3:74-9. 2662683
121. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;2(8519):1300-4. 2662685
122. Feldt-Rasmussen B, Mathiesen ER, Hegedüs L, Deckert T. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. The New England Journal of Medicine 1986;Volume(11):665-70. 2662686
123. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991;34(3):164-70. 2662687
124. Verrillo A, Teresa A, Martino C, Verrillo L, Chiara G. Long-term correction of hyperglycemia and progression of retinopathy in insulin dependent diabetes. A five-year randomized prospective study. Diabetes Research 1988;8(2):71-6. 2662689
125. Hershey T, Bhargava N, Sadler M, White NH, Craft S. Conventional versus intensive diabetes therapy in children with type 1 diabetes: effects on memory and motor speed. Diabetes Care 1999;22(8):1318-24. 2662691
126. Wysocki T, Harris MA, Buckloh LM, Wilkinson K, Sadler M, Mauras N, et al. Self-care autonomy and outcomes of intensive therapy or usual care in youth with type 1 diabetes. Journal of Pediatric Psychology 2006;31(10):1036-45. 2662692
127. Wysocki T, Harris MA, Mauras N, Fox L, Taylor A, Jackson SC, et al. Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months. Diabetes Care 2003;26(4):1100-5. 2662693
128. Wysocki T, Harris MA, Wilkinson K, Sadler M, Mauras N, White NH. Self-management competence as a predictor of outcomes of intensive therapy or usual care in youth with type 1 diabetes. Diabetes Care 2003;26(7):2043-7. 2662694
129. Azar ST, Kanaan N. Intensive insulin therapy compared with conventional insulin therapy does not reduce depressive symptoms in parents of children with type 1 diabetes. Diabetes Care 1999;22(8):1372-3. 2662696
130. Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jørgensen K, Hanssen KF. Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992;35(12):1165-9. 2662698
131. Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. New England Journal of Medicine 2000;342:381-9. Survey of Ophthalmology 2001;45(5):459-60. 2662700
132. Beck-Nielsen H, Olesen T, Mogensen CE, Richelsen B, Olsen HW, Ehlers N, et al. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Research (Edinburgh, Scotland) 1990;15(4):185-90. 2662702
133. Biesenbach G, Grafinger P, Kaiser W, Stuby U, Zazgornik J. [Metabolic control in labile type I diabetes with conventional insulin therapy, basal bolus insulin therapy using pens and continuous subcutaneous insulin infusion with the pump]. [German]. Medizinische Klinik 1988;83(12):398-401. 2662704
134. Bougneres PF, Landais P, Mairesse AM, Jais JP, Jos J, Peyraud J, et al. Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents. A multicenter controlled study. Diabetes Care 1993;16(1):94-102. 2662706
135. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. The Journal of Diabetic Complications 1987;1(3):91-5. 2662708
136. Christiansen JS, Ingerslev J, Bernvil SS, Christensen CK, Hermansen K, Schmitz A. Near normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand factor in insulin-dependent diabetes mellitus: a controlled trial. The Journal of Diabetic Complications 1987;1(3):100-6. 2662710
137. Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabète & Métabolisme 1985;11(1):3-8. 2662712
138. The Italian National Research Council Study Group on Diabetic Retinopathy. The effect of continuous insulin infusion as compared with conventional insulin therapy in the evolution of diabetic retinal ischaemia. Two years report. Diabetes Nutrition & Metabolism - Clinical & Experimental 1989;2(3):209-18. 2662714
139. de Beaufort CE, Houtzagers CMGJ, Bruining GJ, Aarsen RSR, den Boer NC, Grose WFA, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year follow-up of a randomized, prospective trial. Diabetic Medicine 1989;6(9):766-71. 2662716
140. Ditzel J, Clemmensen NK. [A comparative study of intensive conventional insulin treatment and a multiple insulin-injection regimen with NovoPen]. [Danish]. Ugeskrift for Laeger 1987;149(20):1335-8. 2662718
141. Dzien A, Drexel H, Hopferwieser T, Patsch JR, Braunsteiner H. [Effects of intensified insulin therapy on fat metabolism in type 1 diabetes mellitus]. [German]. Deutsche Medizinische Wochenschrift 1988;113(43):1669-72. 2662720
142. Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H. Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year follow-up. Hormone and Metabolic Research 1987;19(9):419-21. 2662722
143. Eschwege E, Job D, Guyot-Argenton C, Aubry J P, Tchobroutsky G. Delayed progression of diabetic retinopathy by divided insulin administration: a further follow-up. Diabetologia 1979;16(1):13-5. 2662724
144. Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabetic Medicine 2006;23(12):1332-8. 2662726
145. Goicolea Opacua I, Hernandez Colau I, Cortazar Galarza A, Vazquez Garcia JA. [Comparison of metabolic control between the continuous subcutaneous insulin infusion pump and augmented conventional treatment. Effects after 12 months]. [Spanish]. Medicina Clinica 1987;88(16):617-20. 2662728
146. Itoh H, Namba M, Kono N, Tarui S. [Multiple insulin injection therapy as intensive insulin therapy]. [Japanese]. Nippon Rinsho 1990;48:1015-21. 2662730
147. Kaufman FR. Intensive management of type 1 diabetes in young children. Lancet 2005;365(9461):737-8. 2662732
148. Kordella T. Tight control can protect your heart. Diabetes Forecast 2005;58(10):44-5. 2662734
149. Kritz H, Hagmuller G, Lovett R, Irsigler K. Implanted constant basal rate insulin infusion devices for Type 1 (insulin-dependent) diabetic patients. Diabetologia 1983;25(2):78-81. 2662736
150. The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA 1988;260(1):37-41. 2662738
151. Levy I, Bergua M, Esmatjes E, Halperin I, Figuerola D. [Unstable type I diabetes mellitus: comparative study between intensive conventional treatment and continuous subcutaneous infusion of insulin]. [Spanish]. Medicina Clinica 1984;83(13):525-8. 2662740
152. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.[Erratum appears in Cariovasc Res 1997 Dec;36(3):460]. Cardiovascular Research 1997;34(1):248-53. 2662742
153. Montanya E, Fernandez-Castaner M, Soler J. Improved metabolic control preserved beta-cell function two years after diagnosis of insulin-dependent diabetes mellitus. Diabetes & Metabolism 1997;23(4):314-9. 2662744
154. Nosadini R, Velussi M, Fioretto P, Doria A, Avogaro A, Trevisan R, et al. Frequency of hypoglycaemic and hyperglycaemic-ketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM. Diabetes, Nutrition & Metabolism - Clinical & Experimental 1988;1(4):289-96. 2662746
155. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year follow-up. Diabetes 1984;33(10):995-1001. 2662748
156. Podgorski G, Taton J, Czech A, Laz R, Szalkiewicz G. [Comparison of the effectiveness of conventional and intensive insulin therapy in the treatment of diabetes mellitus type 1 in pregnant women or those planning pregnancy]. [Polish]. Polski Tygodnik Lekarski 1987;42(50):1571-6. 2662750
157. Rodger NW, Behme MT, Dupre J, Chamberlain MJ. Metabolic effects of continuous subcutaneous insulin infusion: evidence that a rise and fall of portal vein insulin concentration with each major meal facilitates post-absorptive glycemic control. Clinical and Investigative Medicine. Médecine Clinique et Experimentale 1988;11(3):167-86. 2662752
158. Rosenstock J, Challis P, Strowig S, Raskin P. Improved diabetes control reduces skeletal muscle capillary basement membrane width in insulin-dependent diabetes mellitus. Diabetes Research & Clinical Practice 1988;4(3):167-75. 2662754
159. Saito Y, Ohmi G, Tano Y, Kinoshita S. Lens changes during rapid tightening of metabolic control in diabetes. Lancet 1996;347(9017):1764. 2662756
160. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. The New England Journal of Medicine 1993;329(5):304-9. 2662758
161. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. The New England Journal of Medicine 1989;320(9):550-4. 2662760
162. Skare S, Dahl-Jorgensen K, Kriz V, Hanssen KF. Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control. Scandinavian Journal of Clinical and Laboratory Investigation 1986;46(7):635-8. 2662762
163. Tubner RC, Cull CA, Holman RR. Frequency of hypoglycemic episodes during intensive therapy with human insulin. Diabetes Care 1996;19(2):181-2. 2662764
164. Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA. Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit. Metabolism: Clinical and Experimental 2009;58(4):488-91. 2662766
165. Wiseman MJ, Saunders AJ, Keen H, Viberti G. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. The New England Journal of Medicine 1985;312(10):617-21. 2662768
166. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine 1997;157(2):181-8.
167. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
168. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33 Suppl 1:S11-61.
169. Alaveras AE, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrology, Dialysis, Transplantation 1997;12 Suppl 2:71-4.
170. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
171. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. The New England Journal of Medicine 1986;315(4):215-9.
172. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. International Journal of Clinical Practice 2010;64(3):305-15.
173. Beller EM, Chen JK, Wang UL, Glasziou PP. Are systematic reviews up-to-date at the time of publication?. Systematic Reviews 2013;2(1):36. [2046-4053: (Electronic)]
174. Berger M, Mühlhauser I. Implementation of intensified insulin therapy: a European perspective. Diabetic Medicine 1995;12(3):201-8.
175. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic Neuropathies. Diabetes Care 2004;27(6):1458-86.
176. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD007543.pub2]
177. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. BMJ (Clinical Research Ed.) 2009;338:b1870. [PUBMED: 19474024]
178. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; Vol. 32:Suppl 1.
179. Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, et al. Large trials vs meta-analysis of smaller trials: how do their results compare?. JAMA 1996;276(16):1332-8.
180. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16.
181. Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabetic Medicine 2010;27(4):398-404.
182. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57(12):3169-76. [PUBMED: 19033403]
183. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ (Clinical Research Ed.) 1985;290(6471):811-5.
184. Daneman D. Type 1 diabetes. Lancet 2006;367(9513):847-58.
185. Davidson M, Penney ED, Muller B, Grey M. Stressors and self-care challenges faced by adolescents living with type 1 diabetes. Applied Nursing Research 2004;17(2):72-80.
186. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care 1987 Jan-Feb;10(1):1-19.
187. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England Journal of Medicine 1993;329(14):977-86.
188. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics 1994;125(2):177-88.
189. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Archives of Ophthalmology 1995;113(1):36-51.
190. The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. American Journal of Cardiology 1995;75(14):894-903.
191. The Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44(8):968-83. [PUBMED: 7622004]
192. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102(4):647-61.
193. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International 1995;47(6):1703-20.
194. The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45(10):1289-98. [PUBMED: 8826962]
195. The DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.[Erratum appears in JAMA 1997 Jul 2;278(1):25]. JAMA 1996;276(17):1409-15.
196. The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. The New England Journal of Medicine 2011;365(25):2366-76.
197. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26(5):1485-9.
198. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33(6):1389-94. [PUBMED: 20508232]
199. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 2007;147(8):578-81.
200. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009;360(2):129-39.
201. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: A meta-analysis. Diabetic Medicine 1997;14(11):919-28.
202. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution. Nature Clinical Practice. Nephrology 2008;4(3):115.
203. Field LL, Tobias R. Unravelling a complex trait: the genetics of insulin-dependent diabetes mellitus. Clinical and Investigative Medicine 1997;20(1):41-9.
204. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes 2008;26(2):77-82.
205. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney International 2001;59(1):260-9.
206. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):34i-43i.
207. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008;358(24):2545-59.
208. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia 2009;52(1):42-5.
209. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
210. Hansen HP, Tauber-Lassen E, Jensen BR, Parving H-H. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney International 2002;62(1):220-8.
211. Hershey T, Bhargava N, Sadler M, White NH, Craft S. Conventional versus intensive diabetes therapy in children with type 1 diabetes: effects on memory and motor speed. Diabetes Care 1999;8:1318-24.
212. Herzer M, Hood KK. Anxiety symptoms in adolescents with type 1 diabetes: association with blood glucose monitoring and glycemic control. Journal of Pediatric Psychology 2010;35(4):415-25.
213. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
214. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
215. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society) 2009;172(1):137-59.
216. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
217. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
218. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity & Metabolism 2012;14(9):780-8.
219. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201-11.
220. Ingerski LM, Laffel L, Drotar D, Repaske D, Hood KK. Correlates of glycemic control and quality of life outcomes in adolescents with type 1 diabetes. Pediatric Diabetes 2010;11(8):563-71.
221. Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia 1993;36(10):883-92.
222. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
223. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
224. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105(10):1801-15.
225. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. The American Journal of Medicine 1985;78(5):785-94.
226. Larsen JR, Sjoholm H, Hanssen KF, Sandvik L, Berg TJ, Dahl-Jorgensen K. Optimal blood glucose control during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes. Diabetes Care 2003;26(8):2400-4.
227. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: a systematic review and meta-analysis (Structured abstract). Diabetes Care 1999;Suppl 2:B35-9.
228. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
229. Liu D. Combining information for heterogeneous studies and rare events studies. Ph.D. Thesis, Rutgers University. New Brunswick, NJ. 2012. New Brunswick, NJ: Rutgers University, http://mss3.libraries.rutgers.edu/dlr/showfed.php?pid=rutgers-lib:37435 (last accessed 19.06.2013).
230. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. Journal of Diabetes and its Complications 2001;15(6):287-94.
231. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinology and Metabolism Clinics of North America 2010;39(3):481-97.
232. Martin S, Dreyer M, Kiess W, Ldecke H-J, Mller UA, Schatz H, et al. Evidenzbasierte Leitlinie der DDG - Therapie des Diabetes mellitus Typ 1. Deutsche Diabetes Gesellschaft 2007.
233. Mattila TK, Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 2010;70(17):2229-45.
234. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. Journal of Clinical Investigation 1984;74(4):1143-55.
235. McGrady ME, Laffel L, Drotar D, Repaske D, Hood KK. Depressive symptoms and glycemic control in adolescents with type 1 diabetes: mediational role of blood glucose monitoring. Diabetes Care 2009;32(5):804-6.
236. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Medical care 2000;38(6):679-85.
237. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes 2012;61(11):2987-92.
238. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. The Cochrane Database of Systematic Reviews 2010;20(1):CD005103.
239. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. Journal of Internal Medicine 2003;254(1):45-66.
240. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, Obesity & Metabolism 2009;11(4):372-8.
241. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face?. Annals of Internal Medicine 2009;150(11):803-8.
242. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2, 873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care. 1997;20(5):714-20.
243. Muis MJ, Bots ML, Grobbee DE, Stolk RP. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabetic Medicine 2005;22(2):118-26.
244. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005;353(25):2643-53.
245. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Archives of Internal Medicine 2009;169(14):1307-16.
246. CG15 Type 1 diabetes in children, young people and adults: NICE guideline. National Institute for Clinical Excellence 2010.
247. Nicholas J, Charlton J, Dregan A, Gulliford MC. Recent HbA1c values and mortality risk in type 2 diabetes. Population-Based Case-Control Study. PLoS One 2013;8(7):e68008.
248. DMP Diabetes mellitus type 1 [DMP Diabetes mellitus Typ 1]. Qualitätssicherungsbericht: Disease-Management-Programme in Nordrhein 2008.
249. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications--the Linkoping Diabetes Complications Study. Pediatric Diabetes 2009;10(3):168-76.
250. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. Diabetologia 1999;42(12):1395-403.
251. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline KL, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26(5):1374-9.
252. Osterby R, Parving HH, Nyberg G, Hommel E, Jørgensen HE, Løkkegaard H, et al. A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy. Diabetologia 1988;31(5):265-70.
253. Pedrini MT. The Effect of Dietary Protein Restriction on the Progression of Diabetic and Nondiabetic Renal Diseases: A Meta-Analysis. Annals of Internal Medicine 1996;124(7):627.
254. Pimouguet C, Le Goff M, Thiebaut R, Dartigues JF, Helmer C. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. Canadian Medical Association Journal 2011;183(2):E115-27.
255. Pitkaniemi J, Onkamo P, Tuomilehto J, Arjas E. Increasing incidence of Type 1 diabetes--role for genes?. BMC Genetics 2004;5:5:5.
256. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44(12):2203-9.
257. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996;39(8):940-5.
258. Rerkasem K, Rothwell PM. Meta-analysis of small randomized controlled trials in surgery may be unreliable. The British Journal of Surgery 2010;97(4):466-9.
259. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice 2007;13 Suppl 1:1-68.
260. Shalitin S, Phillip M. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy. Diabetes Care 2008;31 Suppl 2:S121-4.
261. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006;19(2):CD003287.
262. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, et al. Risk Factors for Coronary Heart Disease in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care 2004;27(2):530-7.
263. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
264. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. American Heart Journal 2006;152(1):27-38.
265. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The Joslin 50-Year Medalist Study. Diabetes Care 2011;34(4):968-74.
266. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.
267. Sämann A, Mühlhauser I, Bender R, Kloos CH, Müller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005;48(10):1965-70.
268. Tamborlane WV, Bonfig W, Boland E. Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabetic Medicine 2001;18(11):864-70.
269. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. The New England Journal of Medicine 2005;352(4):341-50.
270. Thomsett M, Shield G, Batch J, Cotterill A. How well are we doing? Metabolic control in patients with diabetes. Journal of Paediatrics and Child Health 1999;35(5):479-82.
271. Tu E, Twigg SM, Semsarian C. Sudden death in type 1 diabetes: the mystery of the 'dead in bed' syndrome. International Journal of Cardiology 2010;138(1):91-3.
272. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52(11):2288-98.
273. Valla V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Experimental Diabetes Research 2010:178372.
274. van der Werf N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes/Metabolism Research and Reviews 2007;23(3):169-83.
275. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-79.
276. Wajchenberg BL, Feitosa AC, Rassi N, Lerario AC, Betti RT. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocrine Practice 2008;14(7):912-23.
277. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341(8856):1306-9.
278. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials. Controlled Clinical Trials 1988;9(4):345-64.
279. Weston PJ, Gill GV. Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The 'dead in bed' syndrome revisited. Diabetic Medicine 1999;16(8):626-31.
280. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301(15):1565-72.
281. World Health Organization Study Group. Diabetes mellitus. WHO Technical Report Series 1985;727:17-9.
282. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
283. Yeh H-C, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Annals of Internal Medicine 2012;157(5):336-47.
284. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53(10):2079-85.
285. Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Critical Care 2013;17(1):R2.
286. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. The New England Journal of Medicine 2010;363(15):1410-8.